Clinical Trial Update: A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery [Phase 3]

View source ↗

Summary

This document reports the completion of a Phase 3 study evaluating the combination of nivolumab and ipilimumab in untreated stage 3 non-small cell lung cancer t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | Status: COMPLETED | Results posted: 2025-07-24